Manish Agrawal

M. Agrawal (only initial available in the supplied records) is a clinical researcher active in contemporary psilocybin research with a focus on feasibility, safety, acceptability and implementation of psychedelic-assisted interventions. Their work, as represented in the provided internal database, spans qualitative and clinical-trial methodologies and addresses both individual and group-delivered models of psilocybin therapy. Key projects include qualitative analysis of acceptability of psilocybin-assisted group therapy for patients with cancer and major depressive disorder, a non-randomised open-label trial investigating safety and tolerability of single-dose psilocybin for post-traumatic stress disorder, and studies analysing long-term benefits of single-dose psilocybin in depressed patients with cancer.

In addition to clinical safety and efficacy questions, Agrawal has contributed to work on health-service and implementation dimensions of psychedelic care — notably empirical estimates of cost-savings and access improvements associated with group psychedelic therapy. Across these studies their contributions emphasise interdisciplinary approaches combining clinical outcomes, qualitative patient-centred data and early health-economics considerations to inform scalable models of psychedelic therapy delivery in anxiety, depressive and trauma-related disorders.